Sensorion (FRA:RFM) Other Current Liabilities: €3.25 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:RFM Sensorion SA FRA:RFM
17 GF Score
Price €0.23
! 1 Warning Sign
View Full Analysis

What is Sensorion Other Current Liabilities?

Sensorion FRA:RFM -1.74% 17 Other Current Liabilities is €3.25 Mil as of Dec. 2025. GuruFocus rates FRA:RFM with a GF Score™ of 17/100. The stock has 1 warning sign investors should review.

Sensorion's other current liabilities for the quarter that ended in Dec. 2025 was €3.25 Mil.

Sensorion's quarterly other current liabilities increased from Dec. 2024 (€5.25 Mil) to Jun. 2025 (€5.38 Mil) but then declined from Jun. 2025 (€5.38 Mil) to Dec. 2025 (€3.25 Mil).

Sensorion's annual other current liabilities increased from Dec. 2023 (€4.51 Mil) to Dec. 2024 (€5.25 Mil) but then declined from Dec. 2024 (€5.25 Mil) to Dec. 2025 (€3.25 Mil).

Sensorion Other Current Liabilities Related Terms

Sensorion Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Sensorion's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sensorion Other Current Liabilities Chart

Sensorion Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.66 4.56 4.51 5.25 3.25

Sensorion Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.51 4.91 5.25 5.38 3.25
FRA:RFM
17GF Score
Sensorion SA FRA:RFM
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sensorion Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €3.25 Mil mean?
Sensorion (FRA:RFM) has a Other Current Liabilities of €3.25 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Sensorion.
Is Sensorion's Other Current Liabilities too high?
Sensorion's current Other Current Liabilities is €3.25 Mil. Overall, Sensorion has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Sensorion's Other Current Liabilities compare to VRTX and REGN?
Sensorion's Other Current Liabilities of €3.25 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Sensorion. Sensorion's current Other Current Liabilities is €3.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sensorion stock overvalued right now?
Sensorion (FRA:RFM) has a current Other Current Liabilities of €3.25 Mil. The current Other Current Liabilities is €3.25 Mil. Sensorion's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Sensorion (FRA:RFM), the current Other Current Liabilities is €3.25 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sensorion Business Description

Other Exchanges ALSEN:FranceRFM:Germany
Address 375, rue du Professeur Joseph Blayac, Montpellier, FRA, 34080
Sensorion SA is a France-based clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders. The SENS501 (OTOF-GT) targets deafness caused by mutations of the gene encoding for otoferlin and is currently developed in a Phase 1/2 clinical study, and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. The company's pipeline programs are OTOF-GT (SENS-501), GJB2-GT, GJB2-GT, GJB2-GT, TREAT AND PREVENT, SENS-401 COCHLEAR, SENS-401 CIO, and SENS-401 SSNHL.
17GF Score

Get the complete analysis for FRA:RFM

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.23
Price